Title: Analyzing structure-function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells.
Journal: Nucleic acids research 20161201
Title: CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Journal: Cell reports 20161122
Title: Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
Journal: The New England journal of medicine 20160707
Title: Sulfur and nitrogen mustards induce characteristic poly(ADP-ribosyl)ation responses in HaCaT keratinocytes with distinctive cellular consequences.
Journal: Toxicology letters 20160226
Title: Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.
Journal: Journal of medicinal chemistry 20150910
Title: Mitochondrial reactive oxygen species are scavenged by Cockayne syndrome B protein in human fibroblasts without nuclear DNA damage.
Journal: Proceedings of the National Academy of Sciences of the United States of America 20140916
Title: Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle.
Journal: Cell metabolism 20140603
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.
Journal: Molecular pharmacology 20121001
Title: Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.
Journal: Molecular pharmacology 20120801
Title: Radiation-inducible immunotherapy for cancer: senescent tumor cells as a cancer vaccine.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy 20120501
Title: Poly(ADP-ribose) polymerase 1 inhibition improves coronary arteriole function in type 2 diabetes mellitus.
Journal: Hypertension (Dallas, Tex. : 1979) 20120501
Title: Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120315
Title: A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120315
Title: The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation.
Journal: Cellular and molecular life sciences : CMLS 20120301
Title: Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
Journal: The Journal of biological chemistry 20120203
Title: Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120115
Title: Novel binding mode of a potent and selective tankyrase inhibitor.
Journal: PloS one 20120101
Title: Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.
Journal: PloS one 20120101
Title: Bortezomib-induced 'BRCAness' sensitizes multiple myeloma cells to PARP inhibitors.
Journal: Blood 20111208
Title: Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
Journal: Cell cycle (Georgetown, Tex.) 20111201
Title: Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.
Journal: Cancer biology & therapy 20111115
Title: Veliparib plus temozolomide in metastatic melanoma trends toward increased PFS but results are not statistically significant.
Journal: Oncology (Williston Park, N.Y.) 20111115
Title: Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma.
Journal: Nuclear medicine communications 20111101
Title: Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.
Journal: Cancer science 20111001
Title: Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.
Journal: Cancer research 20110901
Title: Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.
Journal: Cancer research 20110715
Title: Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymerase.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20110701
Title: Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation.
Journal: Molecular cancer therapeutics 20110701
Title: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Journal: The Journal of clinical investigation 20110701
Title: PARP inhibitors: its role in treatment of cancer.
Journal: Chinese journal of cancer 20110701
Title: The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20110601
Title: Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells.
Journal: Nucleic acids research 20110501
Title: N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
Journal: Neuro-oncology 20110501
Title: 5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2).
Journal: Journal of medicinal chemistry 20110414
Title: MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers.
Journal: Cancer research 20110401
Title: PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.
Journal: Acta clinica Belgica 20110101
Title: Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer.
Journal: PloS one 20110101
Title: Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells.
Journal: PloS one 20110101
Title: Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination.
Journal: Nature structural & molecular biology 20101001
Title: Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors.
Journal: Cancer research 20100801
Title: PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
Journal: Cancer research 20100701
Title: A rapid and sensitive method for determination of veliparib (ABT-888), in human plasma, bone marrow cells and supernatant by using LC/MS/MS.
Journal: Journal of pharmaceutical and biomedical analysis 20100501
Title: Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888.
Journal: Biochemistry 20100216
Title: Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates.
Journal: Cancer chemotherapy and pharmacology 20100201
Title: Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100201
Title: Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future.
Journal: Cancer journal (Sudbury, Mass.) 20100101
Title: Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.
Journal: Breast cancer research : BCR 20100101
Title: ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20091201
Title: Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents.
Journal: Journal of medicinal chemistry 20091112
Title: Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas.
Journal: Cancer biology & therapy 20091101
Title: Role of Phase 0 trials in drug development.
Journal: Future medicinal chemistry 20091101
Title: Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways.
Journal: Molecular cancer research : MCR 20091001
Title: Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
Journal: Molecular cancer therapeutics 20090801
Title: Phase 0 trials: a platform for drug development?
Journal: Lancet (London, England) 20090718
Title: Phase 0 clinical trials: an answer to drug development stagnation?
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090601
Title: Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090601
Title: Phase 0 trials for anticancer drug development.
Journal: Nature reviews. Drug discovery 20090601
Title: Phase zero launch.
Journal: Nature biotechnology 20090601
Title: Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.
Journal: Molecular cancer therapeutics 20090201
Title: Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.
Journal: Journal of medicinal chemistry 20090122
Title: 94th RSNA Annual Meeting.
Journal: The Lancet. Oncology 20090101
Title: Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20081101
Title: An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
Journal: Analytical biochemistry 20081015
Title: Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.
Journal: Molecular cancer research : MCR 20081001
Title: Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080901
Title: A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20080801
Title: Phase 0 trials: an industry perspective.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080615
Title: Patient perspectives on phase 0 clinical trials.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080615
Title: Poly (ADP-ribose) polymerase activity regulates apoptosis in HeLa cells after alkylating DNA damage.
Journal: Cancer biology & therapy 20080601
Title: The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.
Journal: Anticancer research 20080101
Title: Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070515
Title: ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070501
Title: Donawho CK, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007 May 1;13(9):2728-37.
Title: Du Y, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016 Feb;22(2):194-201.
Title: Liu F, et al. Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries in vitro and in vivo. PeerJ. 2016 Apr 4;4:e1890.
